

PSS Press Release

September 23, 2016

Precision System Science Co., Ltd. and Diagenode S.A. Collaborate to Develop Diagnostic Assays on a New All-in-One Automation System

Agreement seeks to develop a broad menu of qPCR tests on the new geneLEAD VIII System

Contact: Ms. Fukui MISAKO
Precision System Science Co., Ltd.
88 Kamihongou Matsudo-shi, Chiba 271-0064, Japan
TEL: +81-47-303-4800 FAX: +81-47-303-4810
<http://www.pss.co.jp>
E-mail: fukui@pss.co.jp

Matsudo Japan, and Liege, Belgium (September 30, 2016) – Precision System Science, Co., Ltd. (“PSS”), an innovative company that develops molecular diagnostics instruments, and Diagenode S.A. (“Diagenode”), a leading-edge developer of qPCR-based molecular diagnostic assays for infectious diseases, today announced an agreement that Diagenode will develop and validate, for PSS on an OEM basis, a number of molecular diagnostic assays for infectious diseases. Eight diagnostic assays for respiratory and enteric disease will be validated on the new PSS all-in-one platform geneLEAD VIII, which is set to launch in Europe from January 2017.

“Our agreement with Diagenode represents the first milestone in PSS’s strategy to become a key player in the medium-throughput molecular diagnostics market. The geneLEAD VIII system is a cutting-edge platform that integrates automated nucleic acid technology with qPCR. Diagenode’s high-quality assays will be optimized for our platform to provide rapid and accurate test results to clinicians who make critical treatment decisions,” said Hideji Tajima, President of PSS.

Both companies will also collaborate on the distribution of the PSS platform in Europe. In Q1 2017, Diagenode will initially offer, as a PSS distributor, the new automated platform along with 4 new CE-marked assays for respiratory and enteric diseases in France and Benelux.

“We are pleased to partner with PSS for assay development on the geneLEAD VIII system. PSS offers state-of-the-art instruments for nucleic acid purification and analysis and is a widely recognized leader with more than 20,000 instruments installed worldwide, said Didier Allaer, CEO of Diagenode. “This collaboration leverages Diagenode’s expertise in diagnostics assay development. The performance and the robustness of the geneLEAD VIII enable us to quickly and readily adapt our assays on a fully automated molecular platform.”

Mr. Tajima additionally stated that PSS would also plan to launch the system and assays in several Asian countries in Q1 2017. “Menu expansion will be a key revenue factor for the geneLEAD system. Diagenode will help us consolidate and standardize a broad range of molecular tests that meet the current and future needs of clinicians.”

About Precision System Science, Co., Ltd (PSS)

PSS, located in Matsudo, Chiba Prefecture, Japan, is a leading global provider of laboratory instruments for nucleic acid extraction. The company specializes in the development and production of automated

instruments. PSS is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded as a maintenance and service company for clinical laboratory instruments in 1985, the company has manufacturing, research and development sites in Japan and maintains sales and service networks in the US and Europe. PSS's shares are traded on TSE Mothers under ticker code 7707.

For more information: Contact Precision System Science (ir@pss.co.jp) or visit our website: www.pss.co.jp

About Diagenode Diagnostics

Founded in 2004, Diagenode (<http://www.diagenodediagnostics.com>) is a leading developer of innovative life-science tools and systems for epigenetics and molecular diagnostics. Diagenode develops novel products for the infectious disease diagnostics market and assays for third parties. The company's customers include diagnostics companies and leading public and private clinical laboratories. Diagenode's high performance products provide clinicians with consistent, cost-effective, and robust results.